U.S.-based pharmaceutical company EirGen has been acquired by U.S. drug company OPKO Health for $135 million.
EirGen said that it made a relatively soft approach to the market in February to gauge interest to build to the next level and the focus had to be in the U.S.
OPKO said that the management, research and development, manufacturing and product distribution teams, along with state of the art facilities, together, will create an important, tax-efficient base of operations for the company.
On January 8, 2013, OPKO acquired Canadian private pharmaceutical company Cytochroma.